(NYSE American: MAIA) Climbs Our Watchlist With 5 Explosive Potential Catalysts (2 Analyst Targets)

With the immuno-oncology field expanding quickly

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored (NYSE American: MAIA) Climbs Our Watchlist With 5 Explosive Potential Catalysts (2 Analyst Targets) *Click Here To Get Our Alerts Faster Via SMS* July 8th Greetings Readers, With the immuno-oncology field expanding quickly, a lesser-known company could be moving into the spotlight with an approach that could change the way cancer is treated. The immune checkpoint inhibitor market is rising sharply, increasing from $50.29Bn in 2025 to $58.43Bn in 2026, and is forecasted to reach $123.57Bn by 2031. Positioned within this accelerating space, this company is advancing a therapeutic strategy designed to capitalize on that momentum. Rather than simply following industry trends, its work suggests a shift in how the immune system can be leveraged against some of the most challenging cancers. And back in 2024, when I brought this profile to your attention, it exploded approx. 275% within months. With multiple analyst targets pointing to triple-digit potential upside, a massive market ripe for disruption, and key company insiders making market purchases, this NYSE American profile is topping our watchlist again: *MAIA Biotechnology, Inc. (NYSE American: MAIA)* MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. And based on multiple potential breakout catalysts, MAIA should be considered as watchlist material. Check them out: #1. One Analyst's Target Suggests Over 850% Potential Upside From MAIA's Current Chart Levels. #2. Another Analyst Target Suggests Over 570% Potential Upside From Tuesday's Close. #3. The Company Is Closely Monitoring Patient Outcomes As They Complete International Enrollment In Part C Of Its Phase 2 Expansion Trial. #4. FDA Clearance Is In The Spotlight As The Company Receives Clearance To Open U.S. Enrollment. #5. 2 Company Insiders Jump On Open Market Purchases Hinting At Growing Confidence. But more on those in a second... MAIA's First-In-Class Cancer Telomere Targeting Agent: THIO THIO (aka 6-thio-dG, 6-thio-2’-deoxyguanosine) is a potentially first-in-class small molecule that is the only direct telomere targeting agent currently in clinical development. Telomerase is present in >85% of human cancers and contributes significantly to the proliferation and reproductive immortality of cancer cells. THIO’s in vitro activity has been studied in models of several tumor types with active telomerase. A New Therapeutic Strategy THIO is recognized by telomerase and incorporated into telomeres in cancer cells. Once incorporated, THIO compromises the telomere structure and function, leading to ‘uncapping’ of the chromosome ends and thus resulting in rapid tumor cell death. Low doses of THIO, followed by anti-PD-L1 or anti-PD1 therapy, completely eliminated advanced tumors in preclinical models in vivo, and produced cancer cell specific immune memory, where the immune system continued to be active against the cancer cells after extended periods of time, with no additional treatment. These results demonstrate how the THIO-produced telomere stress increases innate sensing and adaptive anti-tumor immunity, which provides a strong rationale for sequentially combining their telomere-targeted therapy with immunotherapy (Mender et al., 2020). Clinical Development THIO-104 is a multicenter, open-label, randomized Phase 3 clinical trial, designed to evaluate ateganosine’s telomere-targeting anti-tumor activity when followed by PD-(L)1 inhibition in patients with advanced third-line NSCLC who previously did not respond or developed resistance to treatment regimens containing checkpoint inhibitor and/or chemotherapy and have progressed. The trial has two primary objectives: (1) to assess the clinical efficacy of ateganosine compared to investigator’s choice of chemotherapy, using median Overall Survival (OS) as the primary clinical endpoint (2) to evaluate the safety and tolerability of ateganosine in sequential combination with a checkpoint inhibitor. Second-Generation Telomere Targeting Agents MAIA has initiated an early-stage research and discovery program aimed at identifying new compounds capable of acting through similar mechanisms of activity as THIO, such as the targeting and modifying telomeric structures of cancer cells through cancer-cell intrinsic telomerase activity. The main objective for this program is to discover new compounds with potentially improved specificity towards cancer cells relative to normal cells and with potentially increased anticancer activity. MAIA's Pipeline The company's pipeline includes several targeted immuno-oncology therapies for difficult-to-treat cancers: Grab Sources And More Here: Company Website. Company Presentation. ----- As mentioned above, (NYSE American: MAIA) has several explosive potential catalysts to consider right now. Check these out: #1. MAIA Potential Catalyst - One Analyst's Target Suggests Over 850% Potential Upside From MAIA's Current Chart Levels. Last month, Robert LeBoyer, Senior Vice President and equity research analyst with Noble Life Science Partners, reiterated a $14.00 target on MAIA. From Tuesday's closing valuation, that provides MAIA with upside potential over 850%! Check out some key report highlights: Conclusion. Patients in the trial had advanced disease with relapsed NSCLC. We see these data as additional evidence of a sustainable response from combination treatment with ateganosine and cemiplimab. These data are consistent with prior findings showing improvements in overall survival, progression-free survival, and median survival in patients with ICI-resistant and chemo-resistant NSCLC. We are reiterating our Outperform rating and $14 price target. ----- #2. MAIA Potential Catalyst - Another Analyst Target Suggests Over 575% Potential Upside From Tuesday's Close. Back in May, an analyst at Diamond Equity Research provided an update note on their (NYSE American: MAIA) coverage. In the update, they retagged MAIA with a target of $10.27. From Tuesday's close, that target provides MAIA with a potential upside of over 575%. Here's some highlights from the report: Valuation: Building on the strengthened balance sheet and improved funding visibility, our valuation framework for THIO in NSCLC continues to reflect a 35% probability of success (PoS), supported by THIO-104’s advancement into a pivotal Phase 3 trial, encouraging efficacy signals observed in earlier studies, and regulatory momentum, including Fast Track designation. We continue to assume an expected commercialization timeline of 2028, aligning with the anticipated duration of the Phase 3 trial and the regulatory review process. While dilution from the recent capital raise weighs on per-share value, this is partially offset by improved funding visibility, reduced near-term financing risk, and an increased probability of clinical success. Our discount rate remains unchanged at 13.60%. Based on these assumptions, alongside our comparable company analysis, we derive an illustrative valuation of $10.27 per share, contingent on successful execution by the company. ----- #3. MAIA Potential Catalyst - The Company Is Closely Monitoring Patient Outcomes As They Complete International Enrollment In Part C Of Its Phase 2 Expansion Trial. MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer Part C domestic enrollment is underway at three clinical sites in the U.S. CHICAGO, June 25, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that it has completed international enrollment in Part C of its Phase 2 THIO-101 expansion trial evaluating its lead candidate, ateganosine, in advanced non-small cell lung cancer (NSCLC) patients receiving third line (3L) therapy. Ateganosine is an investigational dual-mechanism therapy targeting telomeres and immune activation in difficult-to-treat cancers. THIO-101 Part C patients, who are resistant to prior checkpoint inhibitor (CPI) therapy and chemotherapy, are randomized between MAIA's proposed combination regimen of ateganosine followed by cemiplimab (Libtayo®) and treatment with ateganosine alone for two cycles. International screening was conducted in Taiwan, Turkey, Poland, Hungary, Romania and Georgia, with 41 patients enrolled and receiving treatment. The Part C study is currently screening patients at multiple clinical sites in the United States. "We greatly appreciate the dedication and contributions of the investigators supporting our THIO-101 trial," said Vlad Vitoc, Founder and Chief Executive Officer of MAIA Biotechnology. "With enrollment now complete at the international Part C clinical sites, we are closely monitoring patient outcomes as the data continues to mature, including key efficacy measures such as disease control rate and overall survival, which have remained central endpoints throughout the Phase 2 THIO-101 trial. Meanwhile, patient screening is ongoing at three activated clinical sites in the United States." ... Read the full article here. ----- #4. MAIA Potential Catalyst - FDA Clearance Is In The Spotlight As The Company Receives Clearance To Open U.S. Enrollment. MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion Additional data from THIO-101 trial expansion studies may further support a potential Accelerated Approval filing with FDA FDA-cleared IND updates detail latest efficacy data and enriched manufacturing protocols CHICAGO, June 03, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared an amendment to update its investigational new drug (IND) application which enables MAIA to open U.S. enrollment for the expansion of the Phase 2 THIO-101 trial of its lead candidate, ateganosine, as a treatment for advanced non-small cell lung cancer (NSCLC). Ateganosine is a novel dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Ateganosine sequenced with a monoclonal antibody checkpoint inhibitor is being evaluated as a therapy for patients in ongoing Phase 2 and Phase 3 clinical trials. MAIA obtained FDA clearance of its updated IND highlighting MAIA's improved efficiencies to its manufacturing capabilities, including new manufacturers, formulation and storage conditions for ateganosine, and MAIA is now cleared to enroll patients in the U.S. for the expansion of the Phase 2 THIO-101 study of patients receiving advanced third-line (3L) NSCLC treatment. In addition to the U.S., the THIO-101 study is ongoing at 44 clinical sites in six countries. MAIA recently activated its first U.S. clinical site at Summit Medical Group in New Jersey. In July 2025, the FDA granted Fast Track designation for ateganosine for the treatment of NSCLC. This designation allows for more frequent FDA communication, potential rolling review, and eligibility for Accelerated Approval and Priority Review. The additional data from the expansion studies may further support a filing for FDA Accelerated Approval. "Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks," said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. "To date, data has shown overall survival (OS) beyond two years for eight patients treated with ateganosine in Parts A and B of THIO-101. We believe this bodes well for Parts C and D evaluations which are specific to third-line treatment care only, where the unmet need for improved clinical outcomes is most urgent." K. Robinson Lewis, Senior Vice President and Head of Regulatory and Quality for MAIA, commented, "We are excited about the prospects for our U.S. trials following FDA clearance of our amended IND. The unmet need for effective third-line NSCLC treatments is widespread in the U.S. Based on strong clinical data documented so far, we are confident in the potential of our therapy to address this significant and substantially underserved patient population." ...  Read the full article here. ----- #5. MAIA Potential Catalyst - 2 Company Insiders Jump On Open Market Purchases Hinting At Growing Confidence. MAIA Biotechnology Announces Open Market Purchases by CEO and Director CHICAGO, June 02, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that its founder and CEO Vlad Vitoc, M.D. and Director Stan V. Smith, Ph.D. have increased their ownership positions through open market purchases. Approximately 72,700 shares of MAIA common st-ock were purchased by Dr. Vitoc on June 6, 2026, at an average common st-ock price of $1.3877. Approximately 75,000 shares of MAIA common st-ock were purchased by Dr. Smith on June 6, 2026, at an average common st-ock price of $1.336. "Our continuing in-vest-ments underscore our strong confidence in the telomere-targeting immuno-oncology platform we've established," said Dr. Vitoc. "As the ateganosine program advances toward later-stage development, we believe ateganosine could become an important new standard of care for patients with advanced non-small cell lung cancer." "MAIA continues to advance what I believe is a differentiated approach to cancer treatment with strong scientific rationale and encouraging clinical momentum," Dr. Smith added. "I'm a strong believer in the incredible potential future that MAIA has in contributing to the patients and ... alike." To date, directors and officers of MAIA hold a 20.46% stake in the Company. Read the full article here. ----- MAIA Recap - This NYSE American Idea Has 5 Explosive Potential Catalysts #1. One Analyst's Target Suggests Over 850% Potential Upside From MAIA's Current Chart Levels. #2. Another Analyst Target Suggests Over 575% Potential Upside From Tuesday's Close. #3. The Company Is Closely Monitoring Patient Outcomes As They Complete International Enrollment In Part C Of Its Phase 2 Expansion Trial. #4. FDA Clearance Is In The Spotlight As The Company Receives Clearance To Open U.S. Enrollment. #5. 2 Company Insiders Jump On Open Market Purchases Hinting At Growing Confidence. ----- Coverage is kicked-off on MAIA Biotechnology, Inc. (NYSE American: MAIA). Be on the lookout for updates heading your way shortly. Talk again soon. Sincerely, Kai Parker StockWireNews (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)

SWN Media | 4808 NW 2nd Ave Unit #388 | Boca Raton, FL 33431 US Unsubscribe | Update Profile | Constant Contact Data Notice